biostudies-literatureUnknown11(2)Timsit JFMerck &amp; Co., Inc., Rahway, NJ, USAMSD, France<h4>Background</h4>This study describes the conditions of use of ceftolozane/tazobactam (C/T) and associated outcomes in French hospital settings.<h4>Methods</h4>This was a prospective, multicenter, French observational study. Patients who received at least 1 dose of C/T were included and followed up as per routine clinical practice, until stop of C/T.<h4>Results</h4>A total of 260 patients were enrolled between October 2018 and December 2019 in 30 centers across France. Of these, 177 (68.0%) received C/T as per indication of usage following the results of the antibiogram (documented cases). Among documented patients, the mean age was 61.8 years, 73.4% were males, and 93.8% presented with multidrug-resistant (MDR) bacteria at inclusion. C/T was most frequently prescribed for pneumonia (48.6%), bacteremia (14.7%), complicated intra-abdominal infections (13.0%), or complicated urinary tract infections (9.6%). <i>Pseudomonas aeruginosa</i> was the species most frequently isolated with 212 strains from 155 patients, and 96.2% of these strains were susceptible to C/T. The median duration of C/T treatment was 16.1 days (1-115, n = 176). Complete or partial cure was achieved in 71.7% of patients, C/T was discontinued upon adaptation to microbiology results in 11.3% of patients for the following reasons: treatment failure in 2.8%, death in 4.0%, adverse events in 1.7%, and other in 8.5%.<h4>Conclusions</h4>This is the first prospective observational study of C/T utilization in a health care setting enrolling many patients in France. C/T demonstrated a high rate of clinical effectiveness in MDR infections, confirming it as an effective treatment option for complicated infections in a high-risk population.Open forum infectious diseasesofae037https://www.ebi.ac.uk/biostudies/studies/S-EPMC10883286biostudies-literatureCeftolozane/Tazobactam for the Treatment of Complicated Infections in Hospital Settings-A French Real-world Study.PMC10883286Mootien JBoutoille DTavares LMRuimy RRuiz FCastan BTimsit JFMackosso CBrassac IAkrich BBourge XfalseCeftolozane/Tazobactam for the Treatment of Complicated Infections in Hospital Settings-A French Real-world Study.<h4>Background</h4>This study describes the conditions of use of ceftolozane/tazobactam (C/T) and associated outcomes in French hospital settings.<h4>Methods</h4>This was a prospective, multicenter, French observational study. Patients who received at least 1 dose of C/T were included and followed up as per routine clinical practice, until stop of C/T.<h4>Results</h4>A total of 260 patients were enrolled between October 2018 and December 2019 in 30 centers across France. Of these, 177 (68.0%) received C/T as per indication of usage following the results of the antibiogram (documented cases). Among documented patients, the mean age was 61.8 years, 73.4% were males, and 93.8% presented with multidrug-resistant (MDR) bacteria at inclusion. C/T was most frequently prescribed for pneumonia (48.6%), bacteremia (14.7%), complicated intra-abdominal infections (13.0%), or complicated urinary tract infections (9.6%). <i>Pseudomonas aeruginosa</i> was the species most frequently isolated with 212 strains from 155 patients, and 96.2% of these strains were susceptible to C/T. The median duration of C/T treatment was 16.1 days (1-115, n = 176). Complete or partial cure was achieved in 71.7% of patients, C/T was discontinued upon adaptation to microbiology results in 11.3% of patients for the following reasons: treatment failure in 2.8%, death in 4.0%, adverse events in 1.7%, and other in 8.5%.<h4>Conclusions</h4>This is the first prospective observational study of C/T utilization in a health care setting enrolling many patients in France. C/T demonstrated a high rate of clinical effectiveness in MDR infections, confirming it as an effective treatment option for complicated infections in a high-risk population.2024-01-01T00:00:00Z2024 Feb2026-06-01T10:48:09.062Z2025-02-19T03:51:21.26ZS-EPMC108832863839045810.1093/ofid/ofae037